Episode 71: Medical Paternalism and a Patient Experience With COVID-19

Episode 71: Medical Paternalism and a Patient Experience With COVID-19

Honored to host Barron H Lerner, MD, PhD, a professor of medicine, bioethicist, and 5-time book author at New York University shares his personal journey of contracting and being treated for COVID-19, thoughts on the usefulness of antibody tests and convalescent-based plasma treatment, ethical considerations of treating patients with experimental therapy, and the balance between patient autonomy and physician paternalism. I learned so much from listening to Dr. Lerner; you will for sure enjoy this one.

Related Resources

Dr Nabhan and Dr Lerner have no relevant financial disclosures. More about Barron Lerner:  NYU Langone

This podcast is produced by the Journal of Clinical Pathways.

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 192: The Truth About Liquid Biopsies With Christian Rolfo

Christian Rolfo, MD, PhD, of Mount Sinai Medical Center (now at Ohio State as Chief of Oncology), explores the science and clinical applications of liquid biopsies, including circulating tumor DNA. On this special Healthcare Unfiltered episode, he explains how this cutting-edge approach compares to traditional tissue samples in terms of concordance, sensitivity, and specificity, and

Read More

Episode 191: The Process of Fellowship Applications Demystified

In this special Healthcare Unfiltered podcast, I tackle the fellowship application process using “Hematology/Oncology” fellowship as an example, but this applies to most other fellowships in other disciplines. To better understand the process and the issues, I invited a fellowship program director and a fellow applicant – doesn’t get better than that.

Read More

Episode 190: ASCO Updates in GU Oncology

I am joined on this special Healthcare Unfiltered podcast by Drs. Rana McKay and Petros Grivas to discuss the latest genitourinary oncology research updates from the 2024 ASCO Annual Meeting, covering topics such as the prognostic ability of KIM-1 in kidney cancer, patient-reported outcomes from enfortumab vedotin/pembrolizumab treatment, and the final overall survival update from

Read More